Despite positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from pharmacy benefit managers. These insurers are https://tayasthn320292.mdkblog.com/48192366/copyright-s-vyndamax-faces-is-meeting-pharmacy-benefit-manager-challenges-a-review-at-reimbursement-disputes